Navigation Links
NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2013
Date:7/25/2013

LAWRENCE, Mass., July 25, 2013 /PRNewswire/ --

Highlights:

  • Revenue Increases to $65.5 million, up 11% from Q2'12
  • Home Revenue Increases to $32.7 million, up 6% from Q2'12
  • Company Reaffirms Top Line Revenue Guidance for 2013
  • Company Opens First Center of Excellence
  • Company Expands into Canada
  • NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported second quarter financial results with total revenue at the top end of its guidance range.

    (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

    Revenue for the second quarter of 2013 increased 11% to a record $65.5 million, compared with revenue of $59.0 million for the second quarter of 2012.  The higher revenues were driven by increased adoption of the NxStage® System One™.

    Home revenue increased to $32.7 million for the second quarter of 2013 compared with revenue of $30.7 million for the second quarter of 2012. 

    Critical Care revenue increased to $10.8 million for the second quarter of 2013 compared with revenue of $9.4 million for the second quarter of 2012.  In-center revenue increased to $21.2 million for the second quarter of 2013 compared with revenue of $18.2 million for the second quarter of 2012. 

    NxStage reported a net loss of $3.4 million, or $(0.06) per share for the second quarter of 2013 compared with a net loss of $5.1 million, or $(0.09) per share for the second quarter of 2012.  Net loss for the second quarter of 2013 includes a $1.2 million tax benefit related to the conclusion of a foreign tax audit.

    "Our results reflect solid progress and early benefit from our strategic growth initiatives, including our new direct to patient marketing programs," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage.  "We believe our efforts to further penetrate both the US and international markets are on track to deliver 15 percent annual Home revenue growth in 2014 and beyond."Burbank continued, "Based on our outlook and our continuing progress in key areas, we are reaffirming both our top line revenue and net loss guidance for 2013. Perhaps more importantly, we believe we're setting the Company up for an exciting new chapter of growth in 2014 and beyond."

    Separately, the Company announced the opening of its first dialysis center in St. Louis, MO, through its wholly owned subsidiary, NxStage Kidney Care, Inc.  The move is in line with the Company's strategic centers of excellence initiative to expand patient access to home therapies and the life-changing benefits possible with home and more frequent dialysis using the NxStage System One.

    The Company also announced its expansion into Canada through a newly established entity, NxStage Medical Canada, Inc. Through this new entity, NxStage is marketing and selling the System One and related products and services directly in Canada.  NxStage highlighted that its first Canadian customer has initiated patient treatment with the System One.

    Guidance:

    For the third quarter of 2013, the Company is forecasting revenues to be between $66.5 million and $68.0 million, and a net loss in the range of $4.5 million to $3.5 million, or $(0.07) to $(0.06) per share.  The Company reaffirmed its top line revenue and net loss guidance for 2013.

    Conference Call:NxStage will also host a conference call today, Thursday, July 25, 2013 at 9:00 a.m. Eastern Time to discuss its second quarter financial results.  To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international).  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com.

    A replay of the conference call will be available 2 hours after the completion of the call through August 2, 2013.  To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 98337588.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com.

    About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

    Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or more frequent hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to NxStage's new centers of excellence initiative, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.

    In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.comNon-GAAP Financial Measure

    The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

     NxStage Medical, Inc.Condensed Consolidated Statements of Comprehensive Loss(in thousands, except per share data)(unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2013201220132012Revenues

    $

    65,462$

    59,009$

    127,106$

    115,960Cost of revenues

    40,37536,62078,01972,259Gross profit

    25,08722,38949,08743,701Operating expenses:Selling and marketing

    11,7169,91822,41219,838Research and development

    4,3664,2509,4748,147Distribution

    5,0374,5829,9459,114General and administrative

    8,2396,93016,06313,552Total operating expenses

    29,35825,68057,89450,651Loss from operations

    (4,271)(3,291)(8,807)(6,950)Other expense:Interest expense

    (150)(1,456)(300)(2,649)Other expense, net

    (10)(79)(186)(131)(160)(1,535)(486)(2,780)Net loss before income taxes

    (4,431)(4,826)(9,293)(9,730)(Benefit from) provision for income taxes

    (1,026)237(894)477Net loss

    $

    (3,405)$

    (5,063)$

    (8,399)$

    (10,207)Net loss per share, basic and diluted

    $

    (0.06)$

    (0.09)$

    (0.14)$

    (0.18)Weighted-average shares outstanding, basic and diluted

    60,03657,73359,70655,319Other comprehensive loss

    (704)(297)(559)(124)Total comprehensive loss

    $

    (4,109)$

    (5,360)$

    (8,958)$

    (10,331) NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)June 30,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents

    $

    94,297$

    106,439Accounts receivable, net

    20,83518,990Inventory

    39,34933,504Prepaid expenses and other current assets

    4,9662,534Total current assets

    159,447161,467Property and equipment, net

    42,47036,320Field equipment, net

    13,08210,101Deferred cost of revenues

    34,30538,028Intangible assets, net

    18,58719,819Goodwill

    42,31342,421Other assets

    2,2413,793Total assets

    $

    312,445$

    311,949LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    $

    18,503$

    16,645Accrued expenses

    22,01520,400Other current liabilities

    2,4432,187Total current liabilities

    42,96139,232Deferred revenues

    53,40159,262Other long-term liabilities

    19,43415,864Total liabilities

    115,796114,358Commitments and contingenciesStockholders' equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized;  no

    shares issued and outstanding as of June 30, 2013 and December 31, 2012

    ——Common stock: par value $0.001, 100,000,000 shares authorized; 61,149,562 and

    59,850,117 shares issued as of June 30, 2013 and December 31, 2012, respectively

    6159Additional paid-in capital

    560,020551,594Accumulated deficit

    (353,380)(344,981)Accumulated other comprehensive (loss) income

    (89)470Treasury stock, at cost: 575,895 and 541,584 shares as of June 30, 2013 and December

    31, 2012, respectively

    (9,963)(9,551)Total stockholders' equity

    196,649197,591Total liabilities and stockholders' equity

    $

    312,445$

    311,949 NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Six Months Ended June 30,20132012Cash flows from operating activities:Net loss

    $

    (8,399)$

    (10,207)Adjustments to reconcile net loss to net cash (used in) provided by operating

    activities:Depreciation and amortization

    12,25911,580Stock-based compensation

    5,4356,252Other

    1,2262,345Changes in operating assets and liabilities:Accounts receivable

    (1,853)(1,851)Inventory

    (12,067)(7,809)Prepaid expenses and other assets

    (2,584)(170)Accounts payable

    1,955(946)Accrued expenses and other liabilities

    (1,565)3,038Deferred revenues

    (4,439)(1,346)Net cash (used in) provided by operating activities

    $

    (10,032)$

    886 NxStage Medical, Inc.Revenues by Segment(in thousands)(unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2013201220132012System One segmentHome

    $

    32,671$

    30,693$

    64,130$

    60,246Critical Care

    10,8269,37121,53619,158Total System One segment

    43,49740,06485,66679,404In-Center segment

    21,23818,22939,93835,840Other

    7277161,502716Total

    $

    65,462$

    59,009$

    127,106$

    115,960 NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months Ended June 30,Six Months Ended June 30,2013201220132012Net loss

    $

    (3.4)$

    (5.1)$

    (8.4)$

    (10.2)Less: Depreciation, amortization, interest, and taxes

    5.37.611.914.7Less: Adjusting items*

    (1.4)(0.8)(2.6)(1.0)Adjusted EBITDA

    $

    0.5$

    1.7$

    0.9$

    3.5* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses 


    '/>"/>
    SOURCE NxStage Medical, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. NxStage Congratulates Home Dialyzors United for Securing Policies through the US Department of Transportation to Improve the Air Travel Experience for Home Dialyzors
    2. Jay Shreiner Joins NxStage Board of Directors
    3. NxStage Announces New Agreements with DaVita
    4. NxStage Announces Second Quarter 2013 Investor Conference Schedule
    5. NxStage Reports First Quarter 2013 Financial Results
    6. NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
    7. NxStage Names Robert G. Funari Chairman Of The Board
    8. NxStage Completes Move to Direct Sales In UK
    9. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
    10. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
    11. NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
    (Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
    (Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
    (Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
    (Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
    (Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
    Breaking Medicine News(10 mins):